U.S. markets closed

Blueprint Medicines Corporation (BPMC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
98.22+2.13 (+2.22%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close96.09
Bid98.47 x 1800
Ask99.02 x 800
Day's Range94.03 - 99.17
52 Week Range43.29 - 125.61
Avg. Volume483,503
Market Cap5.693B
Beta (5Y Monthly)0.74
PE Ratio (TTM)17.57
EPS (TTM)5.59
Earnings DateMay 04, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est117.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Recap: Blueprint Medicines Q4 Earnings

    Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate of ($1.62). Revenue of $34,107,000 decreased by 33.82% from the same period last year, which beat the estimate of $29,240,000. Looking Ahead Blueprint Medicines hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 17, 2021 View more earnings on BPMC Time: 08:30 AM ET Webcast URL: https://edge.media-server.com/mmc/p/shp6w5zy Recent Stock Performance Company's 52-week high was at $125.61 52-week low: $43.29 Price action over last quarter: down 8.88% Company Description Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 17, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
    PR Newswire

    Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results

    Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.


    Blueprint Medicines Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 17, 2021 / Blueprint Medicines Corp. (NASDAQ:BPMC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 17, 2021 at 8:30 AM Eastern Time.